ArticleFrontiers in immunology2026
Case Report: Switching secukinumab to bimekizumab in diffuse cutaneous systemic sclerosis after autologous hematopoietic stem cell transplantation: a case follow-up.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diffuse cutaneous systemic sclerosis (dcSSc) is a heterogeneous autoimmune disease characterized by progressive skin fibrosis, vasculopathy and variable organ involvement. Our recent case report about this patient described clinical improvement under IL-17A inhibition with secukinumab for worsening of cutaneous involvement after autologous hematopoietic stem-cell transplantation. We present the extended disease course through 2025. In July 2025 the patient presented with a new flare characterized by cutaneous tightening, dysesthetic sensory symptoms and intermittent pruritus despite ongoing secukinumab therapy. Given the early signs of renewed cutaneous progression and with the aim of preventing further deterioration, treatment was switched to bimekizumab, a dual IL-17A/IL-17F inhibitor. By November 2025 the patient demonstrated resolution of cutaneous symptoms, improvement of modified Rodnan skin score and improved joint stiffness. A single adverse event was mild oral candidiasis. This case follow-up suggests that broader IL-17 pathway inhibition may represent a promising therapeutic approach for selected patients with refractory inflammatory cutaneous manifestations of dcSSc.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.